Modified mRNA Wound Dressing for Diabetic Ulcer Healing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Impaired wound healing in diabetes, particularly in diabetic foot ulcers, is a significant challenge due to chronic inflammation and unsatisfactory efficacy of current therapeutic approaches, necessitating the development of more effective treatments.
Innovation Solution
A recombinant RNA molecule encoding polypeptides such as chitinase-3-like protein 1 (CHI3L1), fibroblast growth factor 2 (FGF-2), interleukin-2 ORF7, and interleukin-17A, chemically modified with pseudouridine or 5-methylcytidine, is delivered via lipid nanoparticles to promote wound healing by enhancing expression of these proteins in wounds.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional therapeutic approaches are used for diabetic foot ulcers, then treatment simplicity is maintained, but wound healing efficacy is insufficient
Solution Approach 1:
The treatment is segmented into multiple functional components delivered by a single wound dressing: (1) modified mRNA molecules encoding specific polypeptides (CHI3L1, FGF-2, IL-2 ORF7, IL-17A) for different wound healing functions, (2) lipid nanoparticle delivery system for targeted transport, (3) chemical modifications (pseudouridine, 5-methylcytidine) for enhanced stability and reduced immunogenicity. This segmentation allows complex therapeutic functions to be delivered through a unified platform.
Solution Approach 2:
The wound dressing employs composite material strategies by combining: (1) modified mRNA molecules with specific polypeptide encoding sequences, (2) lipid nanoparticle carriers with protective and delivery functions, (3) chemical modifications integrated into the nucleotide structure. This composite approach creates a multifunctional therapeutic system that addresses multiple aspects of wound healing simultaneously.
2Reliability
If RNA molecules are delivered without chemical modification, then manufacturing simplicity is maintained, but RNA stability and therapeutic effectiveness are reduced
Solution Approach 1:
The chemical modifications represent parameter changes in the RNA molecule structure: (1) substitution of uridine with pseudouridine to enhance stability and reduce immunogenicity, (2) substitution of cytidine with 5-methylcytidine for similar protective effects, (3) modification of nucleotide composition ratios to optimize therapeutic performance. These parameter changes improve RNA properties while maintaining manufacturability through established chemical synthesis methods.
3Adaptability or versatility
If multiple polypeptides are encoded by separate RNA molecules, then functional versatility is improved, but delivery system complexity increases
Solution Approach 1:
Multiple polypeptide-encoding functions are merged into a single wound dressing formulation. The dressing simultaneously delivers modified mRNA molecules encoding CHI3L1, FGF-2, IL-2 ORF7, and IL-17A through a unified lipid nanoparticle delivery system, eliminating the need for multiple separate treatments while maintaining functional versatility.
Solution Approach 2:
The wound dressing is designed as a universal platform capable of delivering multiple therapeutic polypeptides simultaneously. The lipid nanoparticle system serves multiple functions: protecting various mRNA molecules, facilitating cellular uptake, and enabling co-delivery of different therapeutic agents through a single application.
Data Source
AI summary
In certain aspects, the disclosure relates to devices and methods for treating wounds wherein an acetylcholinesterase inhibitor is delivered to a wound to promote wound healing. In further aspects, metrifonate can be delivered to the wound by time release from a wound dressing. In further aspects a sequence of wound dressings can be applied to the wound to treat different phases of wound healing.